Justin Bowers
Stock Analyst at Deutsche Bank
(1.84)
# 3,498
Out of 4,613 analysts
128
Total ratings
47.2%
Success rate
0.3%
Average return
Main Sectors:
Stocks Rated by Justin Bowers
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintained: Buy | $185 → $300 | $267.49 | +12.15% | 12 | Aug 6, 2026 | |
| WAT Waters | Rated: Hold | $350 → $400 | $406.86 | -1.69% | 11 | Aug 5, 2026 | |
| AVTR Avantor | Maintained: Hold | $25 → $13 | $13.59 | -4.34% | 7 | Jul 30, 2026 | |
| FTRE Fortrea Holdings | Maintained: Hold | $14 → $20 | $18.43 | +8.52% | 7 | Jul 30, 2026 | |
| MEDP Medpace Holdings | Maintained: Hold | $430 → $535 | $590.67 | -9.42% | 4 | Jul 23, 2026 | |
| DHR Danaher | Rated: Buy | $270 → $240 | $204.76 | +17.21% | 11 | Jul 22, 2026 | |
| TMO Thermo Fisher Scientific | Maintained: Buy | $620 → $630 | $594.00 | +6.06% | 10 | Jul 9, 2026 | |
| TECH Bio-Techne | Downgraded: Hold | $66 → $73 | $72.29 | +0.98% | 9 | Jun 26, 2026 | |
| ICLR ICON Public Limited Company | Maintained: Buy | $370 → $188 | $164.51 | +14.28% | 8 | Jun 25, 2026 | |
| TXG 10x Genomics | Maintained: Hold | $17 → $23 | $52.03 | -55.79% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $6.23 | -3.69% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 → $32 | $34.06 | -6.05% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $345 → $315 | $354.07 | -11.03% | 6 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $260 → $220 | $238.70 | n/a | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $155 → $175 | $163.90 | n/a | 8 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $70 | $125.23 | n/a | 1 | Sep 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 | $187.96 | n/a | 1 | Jan 17, 2014 |
Charles River Laboratories International
Aug 6, 2026
Maintained: Buy
Price Target: $185 → $300
Current: $267.49
Upside: +12.15%
Waters
Aug 5, 2026
Rated: Hold
Price Target: $350 → $400
Current: $406.86
Upside: -1.69%
Avantor
Jul 30, 2026
Maintained: Hold
Price Target: $25 → $13
Current: $13.59
Upside: -4.34%
Fortrea Holdings
Jul 30, 2026
Maintained: Hold
Price Target: $14 → $20
Current: $18.43
Upside: +8.52%
Medpace Holdings
Jul 23, 2026
Maintained: Hold
Price Target: $430 → $535
Current: $590.67
Upside: -9.42%
Danaher
Jul 22, 2026
Rated: Buy
Price Target: $270 → $240
Current: $204.76
Upside: +17.21%
Thermo Fisher Scientific
Jul 9, 2026
Maintained: Buy
Price Target: $620 → $630
Current: $594.00
Upside: +6.06%
Bio-Techne
Jun 26, 2026
Downgraded: Hold
Price Target: $66 → $73
Current: $72.29
Upside: +0.98%
ICON Public Limited Company
Jun 25, 2026
Maintained: Buy
Price Target: $370 → $188
Current: $164.51
Upside: +14.28%
10x Genomics
May 8, 2026
Maintained: Hold
Price Target: $17 → $23
Current: $52.03
Upside: -55.79%
May 8, 2026
Maintained: Buy
Price Target: $10 → $6
Current: $6.23
Upside: -3.69%
May 8, 2026
Maintained: Buy
Price Target: $29 → $32
Current: $34.06
Upside: -6.05%
Feb 13, 2026
Maintained: Buy
Price Target: $345 → $315
Current: $354.07
Upside: -11.03%
Jul 29, 2025
Maintained: Buy
Price Target: $260 → $220
Current: $238.70
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $155 → $175
Current: $163.90
Upside: n/a
Sep 16, 2019
Initiated Coverage: Hold
Price Target: $70
Current: $125.23
Upside: n/a
Jan 17, 2014
Maintained: Buy
Price Target: $140
Current: $187.96
Upside: n/a